The China bioprocess instruments market is expected to reach USD 3.06 billion by 2024 owing to the improving economy, rising aging population and increasing prevalence of chronic diseases. Moreover, increasing demand for single-use instruments in disposable applications is anticipated to augment the growth over the projected period.
China was the second largest pharmaceutical market in the world, expected to grow USD 173 billion by 2024, growing at a CAGR of 9.1% owing to the requirement of medication & drugs to cure deadly diseases. Huge investment in biotechnology will primarily drive the growth of the market, as pharma companies deal in innovations for developing medicines and drugs in line with the increasing prevalence of diseases.
With the patents of numerous biopharmaceutical products expiring by 2016, the market is anticipated to provide a lucrative opportunity for contract manufacturers operating in the region. Approval of the trail plan for new drug marketing authorization holder (MAH) in 2016 to produce, conduct clinical trials, and market the products is expected to provide an impetus to the growth of the industry over the next few years.
Increasing demand for bioprocess instruments in the pharmaceutical, research & development, industrial and medical laboratories coupled with the increasing number of these facilities is expected to result in the growth of the market. Change in lifestyle & food consuming habits, and growing levels of air & water pollution have led to increasing occurrence of disease including obesity which has resulted in a rising number of patients diagnosed with cancer, heart disease, diabetes and other chronic conditions. Thus, the healthcare sector is anticipated to create demand for treatment and laboratory services, which will result in the growth of bioprocess instruments market over the forecast period.
Stringent regulatory policies and the high cost of instruments are likely to restrain the bioprocess instruments market in China. The government has been focusing on reducing the fragmentation in the industry by consolidating manufacturers that lack standards in production with larger companies. This move will help in preventing the quality risks and sub-par manufacturers entering the market. Shortage of skilled labor is another challenge in the growth of bioprocessing industry.
Koninklijke Philips N.V., Thermo Fisher Scientific Inc. and Becton, Dickinson and Company were the top three companies in the market in China in 2016. Companies are extensively investing in R&D for innovation and new product development. In addition, companies are adopting the strategy of merger and acquisition to expand their product portfolio.
1.1 Market trends & movement
Chapter 2 Bioprocess Instruments Market Trends: Drivers & Opportunities
2.2 Key industry trends
2.3 Market driver analysis
2.3.1 Rising prevalence of chronic diseases
2.3.2 Growth in R&D activities in biopharmaceutical industry and life sciences
2.3.3 Market restraint
2.3.4 Stringent regulatory policies
2.4 Value chain analysis
2.6 Porter’s Five Forces’ analysis
Chapter 3 Bioprocess Instruments Market, By Type
3.1 Bioprocess instruments market movement, by type, 2016 & 2024
3.2 Cell Expansion
3.2.1 Market estimates and forecast, 2014-2024 (USD Million)
3.3 Flow Cytometry
3.3.1 Market estimates and forecast, 2014-2024 (USD Million)
3.4 Biological Safety Testing
3.4.1 Market estimates and forecast, 2014-2024 (USD Million)
3.5 Cell Line Development
3.5.1 Market estimates and forecast, 2014-2024 (USD Million)
3.6 Tangential Flow Filtration
3.6.1 Market estimates and forecast, 2014-2024 (USD Million)
3.7 Cell Counter
3.7.1 Market estimates and forecast, 2014-2024 (USD Million)
3.8 Cell Culture
3.8.1 Market estimates and forecast, 2014-2024 (USD Million)
3.9 Pyrogen Testing
3.9.1 Market estimates and forecast, 2014-2024 (USD Million)
3.10 Single Use Bioprocessing
3.10.1 Market estimates and forecast, 2014-2024 (USD Million)
3.11 Virus Filtration
3.11.1 Market estimates and forecast, 2014-2024 (USD Million)
Chapter 4 Competitive Landscape
4.1 Competitive landscape analysis, 2016
4.2 Strategic framework
4.3 Potential customer base
4.4 Company market positioning
4.5 Company profiles
18.104.22.168 Company Overview
22.214.171.124 Financial performance
126.96.36.199 Product benchmarking
188.8.131.52 Recent Initiatives
4.5.2 Thermo Fisher Scientific Inc.
184.108.40.206 Company Overview
220.127.116.11 Product benchmarking
18.104.22.168 Financial performance
22.214.171.124 Recent Initiatives
4.5.3 Alere Inc.
126.96.36.199 Company overview
188.8.131.52 Product benchmarking
184.108.40.206 Financial performance
220.127.116.11 Recent Initiatives
4.5.4 Becton, Dickinson and Company (BD)
18.104.22.168 Company Overview
22.214.171.124 Product benchmarking
126.96.36.199 Financial performance
188.8.131.52 Recent Initiatives
4.5.5 Koninklijke Philips N.V.
184.108.40.206 Company Overview
220.127.116.11 Product benchmarking
18.104.22.168 Financial performance
22.214.171.124 Recent Initiatives
4.5.6 PerkinElmer, Inc.
126.96.36.199 Company overview
188.8.131.52 Financial performance
184.108.40.206 Product benchmarking
220.127.116.11 Recent Initiatives
18.104.22.168 Company Overview
22.214.171.124 Financial performance
126.96.36.199 Recent Initiatives
4.5.8 SHIMADZU CORPORATION
188.8.131.52 Company overview
184.108.40.206 Financial performance
220.127.116.11 Product benchmarking
18.104.22.168 Recent Initiatives
4.5.9 CESCO BIOENGINEERING CO., LTD
22.214.171.124 Company overview
126.96.36.199 Product benchmarking
4.5.10 Shanghai RITAI medicine equipment project co., ltd
188.8.131.52 Company overview
184.108.40.206 Product benchmarking
4.6 List of Other Vendors
Chapter 5 Methodology and Scope
5.1 Research Methodology
5.2 Research Scope & Assumptions
5.3 List of Data Sources
*List of Tables and Figures Available on Enquiry.
- Thermo Fisher Scientific Inc.
- Alere Inc.
- Becton, Dickinson and Company (BD)
- Koninklijke Philips N.V.
- PerkinElmer, Inc.
- SHIMADZU CORPORATION
- CESCO BIOENGINEERING CO., LTD
- Shanghai RITAI medicine equipment project co., ltd